That's a good question. I doubt anyone on this board has a definitive answer as to why or why not a BP would act now on our IP, or wait for Ronin's plan to come to fruition. If the value is there then perhaps some negotiating party has been inspired to urgency.
PPHM has Avid, it might have an exosomes test, and it might have some new antibody discovery platform. Those three things mitigate some risk to any company looking to take control of the still unproven PS targeting platform. If negotiations have been underway with our current cast of characters why would a BP want to roll the dice on a whole new and connected group on the other side of the table?
Good to hear about the from the trenches confirmation, JDM. Thanks much for all your open diligence. We live in interesting times.